Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
10 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
U C B from Anderlecht, company number BE0403053608, closed financial year 2025 with a result of € 383.4 million after tax. Compared with financial year 2024, the result moved from € 389.6 million to € 383.4 million. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 12, 2026.
€ 9.2 billion
▲ 1% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 383.4 million
▼ 2% vs 2024
Profit after tax over the fiscal year.
€ 2.3 million
▼ 94% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 276.4 million paid out
72 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
207.2
▲ 15.2 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 77.9 million
▲ 17% vs 2024
€ 376,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 1.1 million
▼ 37% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 2.8 billion
▼ 23% vs 2024
Loans from banks and other lenders, long and short.
€ 17.4 million
▼ 26% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 95 days on average.
€ 12 million
▲ 14% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Profit after taxes | € 209,835,695 | € 274,117,632 | € 389,632,383 | € 383,401,229 | ▼ 2% |
| Equity | € 8,912,700,512 | € 8,927,759,376 | € 9,053,357,793 | € 9,160,338,136 | ▲ 1% |
| Total debts | € 4,047,570,075 | € 4,115,881,042 | € 4,108,517,404 | € 3,296,841,396 | ▼ 20% |
| Cash | € 13,632,702 | € 39,161,262 | € 40,076,529 | € 2,253,653 | ▼ 94% |
| Land & buildings | € 27,103,309 | € 31,676,874 | € 30,706,099 | € 31,084,232 | ▲ 1% |
| Retained profit | € 6,329,641,876 | € 6,344,700,740 | € 6,470,299,157 | € 6,577,279,500 | ▲ 2% |
| Dividend | € 252,318,837 | € 259,058,769 | € 264,033,966 | € 276,420,886 | ▲ 5% |
| Bank debt | € 3,625,593,302 | € 3,650,280,033 | € 3,623,126,278 | € 2,802,386,762 | ▼ 23% |
| Balance sheet total | € 12,985,137,144 | € 13,064,527,571 | € 13,205,512,692 | € 12,509,165,232 | ▼ 5% |
| Employees (FTE) | 189.5 | 189.4 | 192 | 207.2 | ▲ 15.2 |
Key figures of U C B, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to U C B?
What happened at U C B in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Stefaan HEYLEN stepped down as director. NBB
- Jonathan PEACOCK stepped down as director. NBB
- Fiona POWRIE stepped down as director. NBB
- Ulf WIINBERG stepped down as director. NBB
- Rodolfo SAVITZKY stepped down as director. NBB
- Nefertiti GREENE stepped down as director. NBB
- Dolca THOMAS stepped down as director. NBB
- Pierre GURDJIAN stepped down as director. NBB
In short
From € 209.8 million profit in 2022 to € 383.4 million profit in 2025.
Paid € 6 million in corporate taxes since 2022.
Best year ever: 2024, with € 389.6 million profit.
Paid out € 1.1 billion in dividends to the owners in total.
Management
The stake of FINANCIERE DE TUBIZE comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
U C BThe shares are held by FINANCIERE DE TUBIZE (36.3%). It owns 100% of UCB (Investments) LTD, 100% of UCB Pharma Romania SRL, 100% of UCB Pharma SA, 100% of UCB Trading (Shanghai) Ltd., 100% of UCB Bulgaria EOOD and 100% of UCB Pharma Logistics LLC itself.
Directors
According to the 2025 annual accounts
Maëlys CASTELLA
Director
since 2023 · until 2027
Ulf WIINBERG
Director
since 2024 · until 2028
Jan BERGER
Director
since 2023 · until 2027
Jean-Christophe TELLIER
Director
since 2022 · until 2026
Rodolfo SAVITZKY
Director
since 2024 · until 2028
Kay DAVIES
Director
since 2022 · until 2026
Nefertiti GREENE
Director
since 2024 · until 2028
Cédric van RIJCKEVORSEL
Director
since 2022 · until 2026
Stefaan HEYLEN
Director
since 2025 · until 2029
Dolca THOMAS
Director
since 2024 · until 2028
Jonathan PEACOCK
Chairman of the board
since 2025 · until 2029
Pierre GURDJIAN
Director
since 2024 · until 2028
Charles-Antoine JANSSEN
Director
since 2024 · until 2028
Fiona POWRIE
Director
since 2026 · until 2029
Cyril JANSSEN
Director
since 2023 · until 2027
Shareholders
36.3%
Participations
UCB (Investments) LTD
100%
UCB Pharma Romania SRL
100%
100%
UCB Trading (Shanghai) Ltd.
100%
UCB Bulgaria EOOD
100%
UCB Pharma Logistics LLC
100%
UCB Pharma A.S. (TURKEY)
100%
UCB Pharma France SAS
100%
UCB Australia Pty. LTD
100%
UCB S.R.O.
100%
UCB DE MEXICO S.A. de C.V.
100%
UCB Japan Co LTD
100%
UCB Pharma S.A. (Spain)
100%
UCB Pharma LLC (Russia)
100%
UCB (Pharma) Ireland LTD
100%
Vedim Sp. z.o.o.
100%
UCB HUNGARY LTD
100%
UCB Pharmaceuticals (Taiwan) Ltd
100%
UCB Korea Co LTD
100%
UCB Manufacturing Ireland Ltd.
100%
UCB Biopharma S.A.
100%
100%
UCB India Private Ltd
100%
UCB Pharma S.P.A. (Italy)
99.9%
UCB A.E. (Greece)
99.9%
UCB Pharma (Produtos Farmacêuticos) Lda
98.3%
UCB Pharma Sp. z.o.o. (Poland)
78.1%
UCB GMBH
5.2%
Establishments
Establishment units
Physical locations of this company
Researchdreef 60
1070 Anderlecht
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 10 companies are registered at this address.
All companies at this address →UCB Belgium
UCB PHARMA same network
€ 4.6 billion revenue · 2025
UCB Fipar
Fondation Emmanuel Janssen
UCB BIOPHARMA
€ 3.6 billion revenue · 2025
+5 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0403.053.608
- VAT number
- BE 0403.053.608
- Registered office
- Researchdreef 60, 1070 Anderlecht
- Names & denominations
- U C B
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 26 May 1925
- Peppol
- Active · Active since 24 Dec 2025
- Activities · NACE
Managementactiviteiten van holdings
Activiteiten van holdings
Overige zakelijke dienstverlening, neg
Overige zakelijke dienstverlening, n.e.g.
Holdings
Vervaardiging van geneesmiddelen